)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Beyond Air
Beyond Air (XAIR) investor relations material
Beyond Air Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary11 Nov, 2026
Executive summary
Record quarterly revenue of $2.324M, up ~28% YoY and 31% QoQ, supported by first-generation LungFit PH adoption and international sales.
The second-generation LungFit PH PMA supplement remains under FDA review; requested labeling would allow use during air and ground transport.
CY2026 revenue guidance remains $8M; CY2027 guidance remains $16M–$18M, including anticipated second-generation sales pending FDA approval.
H1 operating cash use was $10.5M; management expects additional funding within one year and cited substantial doubt about meeting obligations from cash on hand.
Financial highlights
Quarterly revenue was $2.324M versus $1.818M; gross profit was $197K versus a $298K gross loss, with gross margin improving to ~8% from negative 16%.
Operating expenses declined to $6.172M from $7.363M, narrowing operating loss to $5.975M from $7.661M.
R&D fell to $1.581M from $2.450M as second-generation development neared completion; SG&A declined to $4.591M from $4.913M, partly offset by sales-team hiring.
Other expense rose to $2.200M from $597K, mainly due to higher debt-related interest and a $567K obsolete-inventory charge.
Net loss attributable to common stockholders was $7.818M, or $3.76/share, versus $7.940M, or $24.98/share.
Outlook and guidance
CY2026 revenue guidance remains $8M, excluding second-generation LungFit PH; CY2027 guidance remains $16M–$18M, including anticipated second-generation revenue pending FDA approval.
CY2027 guidance assumes no second-generation revenue in Q1 and revenue in Q2–Q4; management said it does not currently expect a launch-related pushout.
Audit readiness is expected by mid-December, followed by FDA inspection and review; approval timing and outcome remain subject to the FDA.
International distribution agreements cover more than 40 countries, with significant revenue contribution anticipated in FY2027 and beyond.
Fiscal year-end transitions from March 31 to December 31 effective December 31, 2026; a nine-month transition-period Form 10-K/T is expected.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Beyond Air
- Five director nominees and three other proposals are on the Dec. 10, 2026 ballot.XAIR
Proxy filing - Four annual-meeting votes accompany the shift to a December 31 fiscal year-end.XAIRProxy filing
- Four proposals face stockholders amid a fiscal-year transition and new CEO pay terms.XAIRProxy filing
- Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIRCorporate presentation
- Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR12th Annual Cantor Fitzgerald Global Healthcare Conference
- Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIRRegistration filing
- Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIRQ1 2027
- Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIRQ4 2026
- Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIRPiper Sandler 36th Annual Healthcare Conference
Next Beyond Air earnings date
Q3 202712 Feb, 2027
Beyond Air
Next Beyond Air earnings date
Q3 202712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Beyond Air Inc is a medical device and biopharmaceutical company developing inhaled nitric oxide therapies for the treatment of respiratory conditions, and other potential therapeutic applications. The company is headquartered in Garden City, New York, and its shares are listed on the NASDAQ.